Kiromic Biopharma Inc
OTC:KRBP
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0358
1.663
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Kiromic Biopharma Inc
OTC:KRBP
|
10k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.1B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.6B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Kiromic Biopharma Inc
Glance View
Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. The company is headquartered in Houston, Texas and currently employs 59 full-time employees. The company went IPO on 2020-10-16. The firm is focused on discovering, developing and commercializing immuno-oncology applications through its product pipeline. The company is developing a range of product candidates for the treatment of blood cancers and solid tumors. Its lead product candidates include ALEXIS-PRO-1 and ALEXIS-ISO-1. The firm is developing its brand of chimeric antigen receptor (CAR) T cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). The ALEXIS platform of products has been designed to incorporate its Diamond target discovery platform into an off the shelf gamma delta T cell therapy that address the metastatic and progressive locally advanced solid malignancies, including ovarian, malignant pleural mesothelioma and multiple other indications as well. Its Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells.